MitoNEET is an outer mitochondrial membrane protein that binds pioglitzaone (ActosTM), an insulin-sensitizing drug of the thiazolidinedione class used in the treatment of Type II diabetes. This protein has a unique dimeric structure where the two components interact to form a new fold not previously seen in any Fe-S protein structures or in any know protein. This new fold forms a binding domain between two acid labile 2Fe-2S clusters.
Defects in the ability of the mitoNEET protein to control assembly and transfer of Fe-S clusters typically result in mitochondrial dysfunction such as that found in Type II diabetes.
The overall structure is described as a beta rich domain with a strand swap from opposite ends of the primary structure that forms a ‘beta cap’ domain. Crystallographic analysis was performed on isolated and truncated mitoNEET protein (AA33-108) to determine the precise structure of the novel fold. The Fe-S clusters are 16A from each other, oriented close to the outer mitochondrial membrane.
Pioglitzaone, a member of the thiazolidinedione class of insulin-sensitizing drugs has always been thought to work thru the nuclear receptor PPAR-gamma by effecting lipid metabolism and oxidative capacity. Investigators at UC San Diego have demonstrated that it also binds to the 2FE-2S binding site of mitoNEET.
The overall structure is described as a beta rich domain with a strand swap from opposite ends of the primary structure that forms a ‘beta cap’ domain. Crystallographic analysis was performed on isolated and truncated mitoNEET protein (AA33-108) to determine the precise structure of the novel fold. The Fe-S clusters are 16A from each other, oriented close to the outer mitochondrial membrane.
Pioglitzaone, a member of the thiazolidinedione class of insulin-sensitizing drugs has always been thought to work thru the nuclear receptor PPAR-gamma by effecting lipid metabolism and oxidative capacity. Investigators at UC San Diego have demonstrated that it also binds to the 2FE-2S binding site of mitoNEET.
Country | Type | Number | Dated | Case |
United States Of America | Issued Patent | 8,350,007 | 01/08/2013 | 2008-040 |